Swiezy N B, Matson J L, Kirkpatrick-Sanchez S, Williams D E
Johns Hopkins Medical School, USA.
Res Dev Disabil. 1995 Jan-Feb;16(1):75-80. doi: 10.1016/0891-4222(94)00027-7.
Sixty-five mildly to moderately mentally retarded adults from institutional and community placements in Louisiana and Texas with DSM diagnoses of schizophrenia, depression, or no psychopathology were recruited. The primary goal was to establish the validity of the PIMRA's schizophrenic subscale for diagnosing mentally retarded adults. In addition, validity of the depression subscale was replicated. Assessment measures included the informant version of the Psychopathology Instrument for the Mentally Retarded (PIMRA), DSM-III-R checklists for schizophrenia and depression, and a drug response rating. Univariate and multivariate analyses were conducted, as were interrater reliability on all measures. The schizophrenia and depression subscale of the PIMRA were validated. Implications of the research and directions for future study are presented.
招募了来自路易斯安那州和得克萨斯州机构及社区安置点的65名轻度至中度智力发育迟缓的成年人，他们被诊断患有精神分裂症、抑郁症或无精神病理学症状。主要目标是确定用于诊断智力发育迟缓成年人的PIMRA精神分裂症分量表的有效性。此外，还重复验证了抑郁症分量表的有效性。评估措施包括智力发育迟缓者精神病理学量表（PIMRA）的知情者版本、精神分裂症和抑郁症的DSM-III-R检查表以及药物反应评分。进行了单变量和多变量分析，以及所有测量指标的评分者间信度分析。PIMRA的精神分裂症和抑郁症分量表得到了验证。本文还介绍了该研究的意义及未来研究方向。
